What are Neuromuscular blocking agent drugs?

Neuromuscular blocking agent drugs are pharmacologic agents that share a common mechanism (typically targeting Nicotinic acetylcholine receptor at neuromuscular junction). 4 are currently marketed, with 4 more in clinical development.

What are the marketed Neuromuscular blocking agent drugs?

Marketed Neuromuscular blocking agent drugs include injection of NMBA, Extubation U, Neuromuscular Blocking Agents, Botulinum toxin serotype A.

Neuromuscular blocking agent

4 marketed 3 in Phase 3 1 in Phase 2

This page covers all Neuromuscular blocking agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nicotinic acetylcholine receptor at neuromuscular junction, Nicotinic acetylcholine receptor, Nicotinic acetylcholine receptor at the neuromuscular junction.

Targets

Nicotinic acetylcholine receptor at neuromuscular junction · Nicotinic acetylcholine receptor · Nicotinic acetylcholine receptor at the neuromuscular junction · SNAP-25 (synaptosome-associated protein of 25 kDa) · SNARE complex · SNARE complex (synaptobrevin, SNAP-25, syntaxin) · Botulinum toxin type A

Marketed (4)

injection of NMBA · Fondation Ophtalmologique Adolphe de Rothschild · Anesthesia
NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.
Extubation U · Seganest · Anesthesiology
Extubation U is a neuromuscular blocking agent that facilitates endotracheal tube removal.
Neuromuscular Blocking Agents · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Anesthesiology
Neuromuscular blocking agents inhibit acetylcholine binding at the neuromuscular junction, preventing muscle contraction.
Botulinum toxin serotype A · University of California, Los Angeles · Neurology, Dermatology, Ophthalmology
Botulinum toxin serotype A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Phase 3 pipeline (3)

botulinum toxin Type A (32U) · Allergan · Neurology
Botulinum toxin Type A (32U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
Botulinum Toxin Type A Injection [Xeomin] · Assistance Publique - Hôpitaux de Paris · Neurology; Aesthetics
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
botulinum toxin neuromodulator · Galderma R&D · Neurology, Aesthetics, Pain Management
Botulinum toxin blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Phase 2 pipeline (1)

Botulinum Toxin Type A - Vistabel · Galderma R&D · Neurology
Inhibits acetylcholine release at the neuromuscular junction